Development History of Disposable Endoscopes

The development of disposable endoscopes is not intended to fully replace all reusable endoscopes. Instead, it delivers an instrument design that fundamentally reduces cross-contamination risks for scenarios featuring highly complex reprocessing procedures, difficulties in full standardization of compliance, and severe consequences stemming from any procedural deviations.

hospitals began facing prominent conflicts between consistent reprocessing quality of endoscopes and bottlenecks in equipment turnover, creating practical demand for disposable endoscopic solutions. The 2003 SARS outbreak, in particular, greatly heightened medical institutions’ awareness of cross-infection and isolation management, leading to clearer demands for products less reliant on reprocessing.

As hospitals imposed increasingly stringent hospital-acquired infection control standards, demand for endoscopic examinations and minimally invasive interventions continued to surge, and iterative upgrades of upstream imaging and miniaturized components boosted product performance while cutting costs, the value proposition of disposable endoscopes evolved beyond a mere infection control alternative into an integrated solution delivering predictable turnover efficiency and consistent operational experience. This shift ultimately drove their adoption from supplementary equipment in individual departments to large-scale multidisciplinary deployment.

Ambu’s disposable flexible bronchoscope achieved substantial commercialization and established standardized routine usage workflows primarily for respiratory and critical care settings, marking the transition of disposable endoscopes from prototype validation to replicable clinical application.

In the nascent industrial stage, the core breakthrough of early disposable endoscopes lay in deeper integration of discrete light sources, imaging modules and transmission components found in traditional endoscopic systems, creating single-use probes capable of meeting basic visualization requirements. Restricted by the limitations of image sensors, miniature lighting, materials and packaging technologies at that time, such products were mainly deployed in emergency, isolation or high-infection-risk scenarios. Their primary strengths centered on lessened reprocessing workload and shorter instrument preparation time, rather than full parity with reusable devices for complex therapeutic procedures.

Upon entering the commercial launch phase, disposable flexible endoscopes first gained traction in fields prioritizing rapid equipment turnover and infection isolation, with mature standardized usage emerging earliest in respiratory examinations. Rising adoption facilitated the gradual establishment of evaluation frameworks covering safety, image quality, maneuverability and product consistency, alongside clearer regulatory approval pathways. Circa 2013, accumulated experience in product review and market access laid the groundwork for replicating this model across additional product categories. The subsequent performance improvement and category expansion phase shifted the industrial focus of disposable endoscopes from "functional enough" to "premium user experience".

miniaturization and cost reduction of CMOS imaging and miniature lighting components delivered a pivotal leap in performance, drastically improving the image clarity and reliability of disposable endoscopic devices.

disposable endoscopes expanded beyond respiratory applications into specialties such as urology. Key products including disposable ureteroscopes entered extensive clinical introduction, with product iterations focusing on stable deflection control and dependable working channels.

disposable endoscopes gained further recognition from regulators and clinicians, ushering in accelerated cross-category expansion and laying a market foundation for higher penetration rates in subsequent years.

disposable endoscopes entered a phase of widespread large-scale penetration. Their market expansion was driven not by a single technological factor, but by the combined forces of hospital infection control systems, hospital operational demands and medical reimbursement policies.

The 2020 public health emergency elevated infection control to a non-negotiable operational priority, while amplifying demands for process certainty and predictable costs. The "ready-to-use, no reprocessing required" characteristic of disposable endoscopes was rapidly validated within a short timeframe and widely incorporated into hospital management protocols.

Since then, product development has continued to advance toward high-definition imaging, lightweight design and heightened integration. Matching display terminals and data interfaces have adopted modular construction, further lowering barriers to equipment deployment and staff training, and creating favorable conditions for disposable endoscopes to evolve from emergency backup equipment to standard routine

By comparing the development and application journey of disposable endoscope markets in China and the US, prominent disparities can be observed in market maturity and penetration paths between the two regions.

The U.S. market took shape much earlier. It entered commercial application in the early 2010s and gradually completed the transition from trial procurement to routine deployment and process integration within large hospital systems. Accordingly, disposable endoscopes serve as a reliable alternative in infection-prone settings as well as high-turnover environments such as outpatient departments and ambulatory surgery centers. Meanwhile, multinational corporations including Boston Scientific and Ambu have built a comprehensive product portfolio and supporting supply chain in the country.

The U.S. also boasts a more robust foundation of academic and clinical evidence. Constant research published in relevant medical journals has reinforced the consensus that disposable endoscopes deliver comparable image quality alongside streamlined workflows, further sustaining clinical acceptance and long-term large-volume procurement.

In contrast, China’s market only entered the phase of large-scale commercialization after 2020. Rising awareness of hospital-acquired infection prevention and control, coupled with strengthened domestic manufacturing capacity, has jointly driven rapid growth in market demand. Overall, the industry is still in a stage of rapid growth alongside early industrial consolidation.

Current applications are predominantly concentrated in urological and gastrointestinal endoscopy. Expansion into fields such as bronchoscopy and hysteroscopy remains limited to tertiary hospitals and pilot programs. Nevertheless, a full-fledged domestic industrial ecosystem has rapidly taken shape, with leading local enterprises expanding product coverage through multi-category layouts. On the research front, the accumulation of domestic clinical evidence is accelerating, with studies focusing on cost-effectiveness, cross-infection prevention, and performance benchmarking against imported products to underpin broader clinical promotion in the future.